Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK0359 · 3 trials · 3 indications
| Name | Type | Description |
|---|---|---|
| MK0359 | DRUG | - |
Inclusion Criteria: * You are between the ages of 40 and 75 * You have had a history for at least a year of COPD symptoms * You have a history of smoking one pack of cigarettes per day for 10 years Exclusion Criteria: * You have been in a research study with an investigational drug or vaccine in ...
Top 16 of 18 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Novartis AG Sponsored ADR | NVS | 5 | PHASE3 | QVM149, QMF149, Glycopyrronium bromide |
| GSK plc Sponsored ADR | GSK | 10 | PHASE3 | Trelegy Ellipta, Depemokimab, HFA-152a, GSK5784283, Ventolin |
| Teva Pharmaceutical Industries Limited Sponsored ADR | TEVA | 4 | PHASE3 | TEV-56248, ProAir (albuterol sulfate eMDPI), Budesonide/Formoterol SPIROMAX, Reslizumab |
| Sanofi SA Sponsored ADR | SNY | 8 | PHASE3 | Dupilumab, Lunsekimig |
| AstraZeneca PLC | AZN | 28 | PHASE3 | Benralizumab, Tezepelumab, Budesonide/formoterol, Albuterol/budesonide, PT007 |
| Pfizer Inc. | PFE | 4 | PHASE3 | Tilrekimig, PF-07275315, PF-08103402 |
| Generate Biomedicines, Inc. | GENB | 3 | PHASE3 | GB-0895 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Eli Lilly and Company | LLY | 1 | PHASE2 | Brenipatide |
| Incyte Corporation | INCY | 1 | PHASE2 | povorcitinib |
| Upstream Bio, Inc. | UPB | 1 | PHASE2 | Verekitug |
| Arrowhead Pharmaceuticals, Inc. | ARWR | 1 | PHASE2 | ARO-RAGE |
| Amgen Inc. | AMGN | 1 | PHASE1 | AMG 691 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Apogee Therapeutics, Inc. | APGE | 1 | PHASE1 | APG777 |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE1 | CDX-622 |
MK0359 is an investigational small molecule being developed by Merck & Company, Inc. for respiratory and inflammatory conditions, including chronic obstructive pulmonary disease (COPD), rheumatoid arthritis, and chronic asthma. It has been studied in Phase 2 clinical trials for these indications.
MK0359 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK. The company has sponsored clinical trials of MK0359 in patients with COPD, rheumatoid arthritis, and asthma.
MK0359 is in Phase 2 clinical development. It has completed Phase 2 trials in chronic obstructive pulmonary disease, rheumatoid arthritis, and asthma. MK0359 is investigational and has not been approved by regulatory authorities.
MK0359 has completed three Phase 2 trials: NCT00482235 in COPD (45 participants), NCT00482417 in rheumatoid arthritis (11 participants), and NCT00482898 in asthma (56 participants). All trials are completed, with a combined enrollment of 56 participants.
MK0359 is a distinct investigational compound developed by Merck & Company, Inc. No alternative names for MK0359 have been reported. It is being studied for its potential effects in respiratory and inflammatory diseases.